JPMorgan Raises WUXI APPTEC Target to HK$172, Keeps Overweight Rating

Stock News04-29

JPMorgan released a research report stating that WUXI APPTEC's (02359, 603259.SH) first-quarter results significantly exceeded expectations across multiple metrics, with its stock price surging 14% in a single day following the earnings announcement. The post-earnings conference call further confirmed that performance was substantially ahead of forecasts, with fiscal year 2026 profit margins expected to surpass those of 2025. Demand growth appears broad-based, with strength in small-molecule R&D and manufacturing (D&M) driven not only by oral GLP-1 drugs; management also hinted at a potential update to full-year guidance with the second-quarter results. The bank believes the strong first-quarter margins reflect improvements in business mix and execution, rather than short-term, one-off factors. JPMorgan maintained its "Overweight" rating on WUXI APPTEC, reiterating it as a top pick within the Chinese CXO sector. The H-share target price was raised from HK$150 to HK$172, while the A-share target was increased from 150 yuan to 155 yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment